Mark S. Huberman

6.6k citations

80 papers · 4.5k indexed · 2 hit papers · h-index 30

Impact in

Oncology top 0.5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes

Papers in

Pulmonary and Respiratory Medicine 63
- Lung Cancer Treatments and Mutations 53
- Lung Cancer Diagnosis and Treatment 21
- Gastric Cancer Management and Outcomes 7
Oncology 48
- Lung Cancer Research Studies 22
- Colorectal Cancer Treatments and Studies 12

Co-authors: Daniel B. Costa Susumu Kobayashi Paul A. VanderLaan Daniel G. Tenen Balázs Halmos Eric K. Rowinsky Deepa Rangachari Daniel D. Karp
Journals: Journal of Thoracic Oncology (14 papers)Lung Cancer (13 papers)Journal of Clinical Oncology (11 papers)Cancer (4 papers)Clinical Lung Cancer (4 papers)
Partner nations: United States Israel Singapore

In The Last Decade

Mark S. Huberman

80 papers receiving 4.4k citations

Hit Papers

align trajectories log scale

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers 2015 · 348 citations

Peers

Countries citing papers authored by Mark S. Huberman

Since Specialization

Citations

This map shows the geographic impact of Mark S. Huberman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Huberman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Huberman more than expected).

Fields of papers citing papers by Mark S. Huberman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Huberman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Huberman. The network helps show where Mark S. Huberman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark S. Huberman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark S. Huberman Line = papers co-authored together Mark S. Huberman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas Clinical Cancer Research ·Susan E. Jorge, Antonio R. Lucena‐Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu Kobayashi, Daniel B. Costa	2018	51
2	Tumor biomarker testing in non-small-cell lung cancer: A decade of change Lung Cancer ·Paul A. VanderLaan, Deepa Rangachari, Adnan Majid, Mihir Parikh, Sidhu P. Gangadharan, Michael S. Kent, 王舒芳, Mark S. Huberman, Susumu Kobayashi, Daniel B. Costa	2018	40
3	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer Journal of Thoracic Oncology ·E Barsotti, Henry Aoki, Giulia C. Leonardi, Anika E. Adeni, E. E. N., Christine Lydon, Deepa Rangachari, Mark S. Huberman, Kartik Sehgal, Meghan Shea, Paul A. VanderLaan, Matthew P. Cheng, Francisco M. Marty, Sarah P. Hammond, Daniel B. Costa, Mark M. Awad	2018	69
4	P1.02-031 Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation with Clinical Outcomes Journal of Thoracic Oncology ·Paul A. VanderLaan, Deepa Rangachari, Susan M. Mockus, Justyna Pluta, Honey V. Reddi, Dębski, Mark S. Huberman, Loren Joseph, Susumu Kobayashi, Daniel B. Costa	2017	1
5	Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice Cancer Treatment and Research Communications ·Deepa Rangachari, Lauren Drake, Mark S. Huberman, 王舒芳, Paul A. VanderLaan, Erik Folch, Daniel B. Costa	2016	7
6	Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma Journal of Thoracic Oncology ·Meghan Shea, Mark S. Huberman, Daniel B. Costa	2016	15
7	EGFR Testing in Advanced Non–Small-Cell Lung Cancer, A Mini-Review Clinical Lung Cancer ·Yuri Sheikine, Deepa Rangachari, 王舒芳, Mark S. Huberman, Maria Naelma. Souto, Paul A. VanderLaan, Daniel B. Costa	2016	45
8	De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers Lung Cancer ·Antonio R. Lucena‐Araujo, Amruta Pattar, Paul A. VanderLaan, Dora Dias‐Santagata, Erik Folch, Adnan Majid, Michael S. Kent, Sidhu P. Gangadharan, Deepa Rangachari, Mark S. Huberman, Susumu Kobayashi, Daniel B. Costa	2016	16
9	Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers Lung Cancer ·Deepa Rangachari, Norihiro Yamaguchi, Paul A. VanderLaan, Erik Folch, Anand Mahadevan, Scott Floyd, Erik J. Uhlmann, Eric T. Wong, Suzanne E. Dahlberg, Mark S. Huberman, Daniel B. Costa Hit paper breakdown →	2015	348
10	Experience with targeted next generation sequencing for the care of lung cancer: Insights into promises and limitations of genomic oncology in day-to-day practice PubMed ·Deepa Rangachari, Paul A. VanderLaan, Xiuning Le, Erik Folch, Michael S. Kent, Sidhu P. Gangadharan, Adnan Majid, Richard L. Haspel, Loren Joseph, Mark S. Huberman, Daniel B. Costa	2015	21
11	De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors Lung Cancer ·Xiuning Le, Neelam V. Desai, Adnan Majid, Btr Taylor, Mark S. Huberman, Deepa Rangachari, Michael S. Kent, Sidhu P. Gangadharan, Erik Folch, Paul A. VanderLaan, Daniel B. Costa	2015	23
12	Adequacy of Pleural Fluid Cytology and Pleural Biopsies for Multiple Tumor Genotyping Techniques in Non-small Cell Lung Cancer CHEST Journal ·Erik Folch, Adnan Majid, Paul A. VanderLaan, Norihiro Yamaguchi, Sidhu P. Gangadharan, Michael S. Kent, Richard I. Whyte, Olivier Kocher, David Boucher, Mark S. Huberman, Michael A. Goldstein, Daniel B. Costa	2014	1
13	Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors Journal of Thoracic Oncology ·Susumu Kobayashi, Inas Abdulameer Abbood, Alexandra S. Bailey, Sohei Nakayama, Norihiro Yamaguchi, Michael A. Goldstein, Mark S. Huberman, Daniel B. Costa	2012	171
14	Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations Journal of Thoracic Oncology ·Wee-Lee Yeo, Gregory J. Riely, Beow Y. Yeap, Michelle Lau, Jeremy L. Warner, 小池拓自, Mark S. Huberman, Mark G. Kris, Daniel G. Tenen, William Pao, Susumu Kobayashi, Daniel B. Costa	2010	66
15	A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer Journal of Thoracic Oncology ·Rebecca S. Heist, Panos Fidias, Mark S. Huberman, Blair Ardman, Lecia V. Sequist, Jennifer S. Temel, Thomas J. Lynch	2008	24
16	P3-096: Phase II study of erlotinib in chemo–naïve women with advanced pulmonary adenocarcinoma. Journal of Thoracic Oncology ·David M. Jackman, Neal I. Lindeman, Joan Lucca, Gerd Manhaupt, Michael S. Rabin, Judith Marcoux, Mark S. Huberman, Bruce E. Johnson, Pasi A. Jänne	2007	1
17	Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib Clinical Cancer Research ·David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal I. Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balázs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne	2006	491
18	Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial Cancer Chemotherapy and Pharmacology ·Tomislav Dragovich, Mark S. Huberman, Daniel D. Von Hoff, Eric K. Rowinsky, Paul I. Nadler, Debra L. Wood, Marta Hamilton, Mohammed Faisal Ebrahim, Julie Wolf, Amita Patnaik	2006	40
19	Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma Diseases of the Colon & Rectum ·Pedro Sanz-Altamira, Liam D. Spence, Mark S. Huberman, Marshall R. Posner, Glenn Steele, Laura J. Perry, Keith Stuart	1997	82
20	Trials of 9‐Amino‐20(S)‐Camptothecin in Boston Annals of the New York Academy of Sciences ·Joseph P. Eder, Eric H. Rubin, Richard M. Stone, Caitlin Corker Relph, Mansi Pandya, Jeffrey G. Supko, Nancy M. Kinchla, Thomas Lynch, Selwyn J. Hurwitz, Abu Saadeh, Olayinka Longe, Deborah Toppmeyer, Michael L. Grossbard, J. T. Fowler, Mark S. Huberman, Mariana de Moura Gonçalves, Lawrence N. Shulman, Donald Küfe	1996	9

About Mark S. Huberman

Mark S. Huberman is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Hepatology and Epidemiology, having authored 80 papers that have together received 4.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (53 papers), Lung Cancer Research Studies (22 papers), Lung Cancer Diagnosis and Treatment (21 papers), Cancer Genomics and Diagnostics (13 papers), Colorectal Cancer Treatments and Studies (12 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Gastric Cancer Management and Outcomes (7 papers) and Cancer therapeutics and mechanisms (6 papers). The work is most often cited by research in Oncology (3.0k citations), Pulmonary and Respiratory Medicine (3.3k citations), Cancer Research (778 citations), Hepatology (184 citations) and Genetics (228 citations). Mark S. Huberman has collaborated with scholars based in United States, Israel and Singapore. Frequent co-authors include Daniel B. Costa, Susumu Kobayashi, Paul A. VanderLaan, Daniel G. Tenen, Balázs Halmos, Eric K. Rowinsky, Deepa Rangachari, Daniel D. Karp, P. Santabárbara and Abraham Chachoua. Their work appears in journals such as Journal of Thoracic Oncology, Lung Cancer, Journal of Clinical Oncology, Cancer and Clinical Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact